MSK Biomarker Ctte: Difference between revisions
Jump to navigation
Jump to search
| Line 9: | Line 9: | ||
'''Approved call summaries:''' | '''Approved call summaries:''' | ||
*[[Media:2021_02-23_QIBA_MSK_BC_Call_Summary-FINAL.pdf|February 23, 2021]] | |||
*[[Media:2021_01-26_QIBA_MSK_BC_Call_Summary-FINAL.pdf|January 26, 2021]] | *[[Media:2021_01-26_QIBA_MSK_BC_Call_Summary-FINAL.pdf|January 26, 2021]] | ||
*[[Media:2020_10-27_QIBA_MSK_BC_Call_Summary-FINAL.pdf|October 27, 2020]] | *[[Media:2020_10-27_QIBA_MSK_BC_Call_Summary-FINAL.pdf|October 27, 2020]] | ||
'''''[[MSK Biomarker Committee Call Summaries Archive]]''''' | '''''[[MSK Biomarker Committee Call Summaries Archive]]''''' | ||
Revision as of 16:18, 23 March 2021
Co-chairs: Xiaojuan Li, PhD; Thomas M. Link, MD, PhD
RSNA Staff Support: Susan Stanfa
The MSK Biomarker Committee seeks to develop a quantitative Profile for MSK.
Meetings
Approved call summaries:
MSK Biomarker Committee Call Summaries Archive
Working Documents
- QIBA MSK Profile 2020-01-28: MR-based cartilage compositional biomarkers (T1ρ, T2) for risk prediction, early diagnosis and monitoring of treatment of degenerative joint disease